Skip to search formSkip to main contentSkip to account menu

Selegiline

Known as: L-Deprenyl, (-)-selegiline, Selegiline [Chemical/Ingredient] 
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow… 
National Institutes of Health

Related topics

Related topics

29 relations

Narrower (10)

4-fluorodeprenylDeprenylE-250Eldepryl
Alzheimer's DiseaseAttention deficit hyperactivity disorderDepressive disorderDrug Allergy

Broader (3)

Antiparkinson AgentsMonoamine Oxidase InhibitorsNeuroprotective Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Possible serotonin syndrome arising from an interaction between nortiptyline and selegiline in a lady with parkinsonism
Sirs: A 47-year-old Iranian woman presented with an abrupt onset of increasing confusion, immobility, and involuntary tremor of… 
1995
1995
Hair analysis for drugs of abuse. IX. Comparison of deprenyl use and methamphetamine use by hair analysis.
Deprenyl (DPN) and its metabolites, desmethyl deprenyl (desmethyl DPN), methamphetamine (MA) and amphetamine (AP), in the hair of… 
1993
1993
Preclinical Evaluation of l-Deprenyl: Lack of Amphetamine-Like Abuse Potential
l-Deprenyl is a useful and effective drug in the clinical treatment of parkinsonism and holds promise for treatment of Alzheimer… 
1991
1991
Psychiatric effects of selegiline.
To the Editor. —The exciting news that selegiline (deprenyl, Eldepryl) may retard the progression of early Parkinson's disease, 1… 
1986
1986
Studies of monoamine oxidase and semicarbazide-sensitive amine oxidase. I. Inhibition by a selective monoamine oxidase-B inhibitor, MD 780236.
In vitro studies of the effect of MD 780236, a selective monoamine oxidase (MAO)-B inhibitor, on a semicarbazide-sensitive amine… 
1984
1984
Enzymic and molecular characteristics of a new form of monoamine oxidase, distinct from form-A and form-B.
The present study was undertaken to clarify the enzymic and molecular properties of monoamine oxidase (MAO) in carp brain. In… 
1983
1983
L-deprenyl in the treatment of Parkinson's disease.
The experiences of a six years' follow-up study with L-Deprenyl are summarized. L-Deprenyl may be effective in influencing the… 
1982
1982
The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression.
1982
1982
Differential efficacy of L-deprenyl, a selective MAO type-B inhibitor, in endogenous and nonendogenous depression.
1979
1979
Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
Fluctuations in performance in levodopa-treated Parkinsonians pose frequent and difficult problems of managment. Controlled… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)